



**Management of posttransplant anemia attributed to sirolimus.** ACE, angiotensin-converting enzyme; Hb, hemoglobin; MPA, mycophenolic acid; MMF; mycophenolate mofetil; PT, posttransplant; SRL, sirolimus; TSAT, transferrin saturation.

- (1) Kaplan, B., Qazi, Y., & Wellen, J. R. (2014). Strategies for the management of adverse events associated with mTOR inhibitors. *Transplantation Reviews*, 28(3), 126–133.
- (2) Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB. Posttransplant anemia: the role of sirolimus. *Kidney Int* 2009; 76:376–82.
- (3) Diekmann F, Rovira J, Diaz-Ricart M, et al. mTOR inhibition and erythropoiesis: microcytosis or anaemia? *Nephrol Dial Transplant* 2012; 27:537–41.
- (4) Fishbane, S., Cohen, D. J., Coyne, D. W., Djamali, A., Singh, A. K., & Wish, J. B. (2009). Posttransplant anemia: the role of sirolimus. *Kidney International*, 76(4), 376–382.
- (5) Oppenheimer F, Alonso A, Arias M, Campistol JM, González Molina M, González Posada JM, Grinyo JM, Morales JM, Sánchez Fructuoso A, Sánchez-Plumed J, Ruiz JC. Handling sirolimus in clinical practice. *Spanish Nephrology Society. Nefrologia*. 2006;26 Suppl 2:64-93. English, Spanish. PMID: 17937635.

